Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02724085 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

A Phase 1 study of Pneumonia, sponsored by Tetraphase Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
57
Enrollment target
1
Study location

NCT02724085 is a Phase 1 study of Pneumonia that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 57 participants, below the 4,518-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02724085, a Phase 1 study of Pneumonia, has completed, sponsored by Tetraphase Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Conditions Studied

Interventions

  • DRUG TP-271

Study Locations (1)

Texas

  • PPD Phase 1 Clinic - Austin

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2015-12-18
Est. Completion 2016-12-12
Phase Phase 1

Sponsor

Tetraphase Pharmaceuticals

13 total trials

What the Registry Record Tells You About NCT02724085

The ClinicalTrials.gov registry entry for NCT02724085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,518-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which TP-271 is the first listed.

NCT02724085 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02724085 about?

NCT02724085 is a clinical study titled "A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271". This is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this stu...

What is the current status of trial NCT02724085?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2015-12-18. Estimated completion is 2016-12-12.

What conditions does trial NCT02724085 study?

This clinical trial studies the following conditions: Pneumonia.

What interventions are being tested in trial NCT02724085?

The interventions under investigation include: TP-271 (DRUG).

Who is sponsoring clinical trial NCT02724085?

This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02724085 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.